

ASX ANNOUNCEMENT

Notice under Section 708AA(2)(f) of the Corporations Act 2001

10 May 2019

Analytica Limited (Company) has today announced a non-renounceable pro-rata entitlement offer to raise up to approximately \$2.7 million, before offer costs (**Entitlement Offer**).

The Entitlement Offer will be open to shareholders of the Company with a registered address in Australia and New Zealand (**Eligible Shareholders**).

Under the Entitlement Offer, Eligible Shareholders can subscribe for 1 fully paid ordinary share (**New Share**) for every 6 existing shares in the Company held as at 7pm (Sydney time) on Wednesday, 15 May 2019 (**Record Date**) at an issue price of 0.5 cents per New Share.

The Company advises that it will offer the New Shares for issue to investors under Part 6D.2 of the Corporations Act 2001 (Cth) (**Act**) and states that this notice is given to ASX under paragraph 708AA(2)(f) of the Act, as modified by ASIC Corporations (Non-Traditional Rights Issues) Instrument 2016/84.

Accordingly, the Company advises:

- 1 The Company will offer the New Shares under the Entitlement Offer without disclosure to Eligible Shareholders under Part 6D.2 of the Act.
- 2 As at the date of this notice, the Company has complied with:
 - (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
 - (b) section 674 of the Act.
- 3 As at the date of this notice there is no excluded information as defined in section 708AA(8) and section 708AA(9) of the Act which is required to be disclosed by the Company.
- 4 The potential effect the Entitlement Offer will have on the control of the Company, and the consequences of that effect will depend on the level of participation by Eligible Shareholders. If all Eligible Shareholders take up their entitlement under the Entitlement Offer, the Entitlement Offer will have no effect on the control of the Company. However, the proportional shareholdings of shareholders who are not Eligible Shareholders may be diluted as those shareholders are not entitled to participate in the Entitlement Offer. If an Eligible Shareholder does not take up their entitlement in full, there may be a dilutionary effect on that shareholder's proportionate shareholding.

In the event of a shortfall, the Directors reserve the right to place the shortfall at their sole discretion. Acceptance of entitlements or the placement of any shortfall may also result in existing shareholders or new investors significantly increasing the interest in the Company or obtaining a substantial interest in the Company.



For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance for urinary incontinence in Australia and has CE mark and USFDA 510(k) clearance.

PeriCoach also has clearance in Australia, and CE Marking in Europe for the treatment of pelvic organ prolapse, a condition that affects up to 1 in 5 women during their lifetime.

The product is available for sale from pericoach.com in Australia, New Zealand, UK and Ireland, and the USA.

